Found 469 results in Expert Content

Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.

Summary: Low bioavailability can lead to development challenges. Advanced formulation expertise and technologies can increase the chance of success in the clinic.

Summary: Unique combo formula containing LONGVIDA® Curcumin Extract intended to support joint comfort.

Summary: Leveraging Catalent’s expert formulation and dose design capabilities, Kemin Industries has developed a new to the segment nutritional supplement which includes their proprietary phenolic complex Neumentix™ derived from spearmint.

Summary: With over 80 years of global manufacturing expertise, Catalent has an extensive network of facilities to provide full service integrated softgel manufacturing and coating capabilities.

Summary: EasyBurst® chewable technology is an ideal platform to deliver active ingredients, without the need for water, using our advanced taste masked fills encapsulated in our proprietary softgel shells.

Summary: As your innovation partner, we will help you address your consumers’ needs by leveraging our differentiated softgel technologies and robust product library to give your brand a competitive advantage in the market.

Summary: Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, recently sat down for an interview...

Summary: Big Pharma used to ignore this segment of the market, but now developing orphan drugs to treat these rare diseases is an industry priority.

Summary: In this report, we will highlight the trends shaping the orphan-drug market, with a particular focus on expedited drug development. Expert insights on navigating development and manufacturing challenges with...